About Us
CRISPRomics®
+
CRISPRomics®
Publications
Pipeline
+
Pipeline®
Expanded Access Policy
News
People
+
Leadership Team
Board of Directors
Careers
Contact
Follow us on Twitter
Find us on LinkedIn
AACR Poster Presentation: “KSQ-001: A CRISPR/Cas9-Engineered Tumor Infiltrating Lymphocyte (eTIL™) Therapy for Solid Tumors
June 22, 2020
AACR Poster Presentation: “KSQ-001: A CRISPR/Cas9-Engineered Tumor Infiltrating Lymphocyte (
e
TIL®) Therapy for Solid Tumors
Click to download PDF file.
© 2023 KSQ Therapeutics, Inc. All rights reserved.